{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-23-000134","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2023-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.809774+00:00","generated_at":"2026-06-07T14:13:44.750648+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Caribou reaches FDA alignment on CB-010 phase 3 trial design; CMO to depart Dec 31","bullets":["FDA accepts comparator arm of platinum-based immunochemotherapy + HDCT + ASCT for CB-010 phase 3 in 2L r/r LBCL.","Phase 3 pivotal trial initiation planned by year-end 2024; RP2D and initial dose expansion data expected Q2 2024.","CB-010 is first allogeneic anti-CD19 CAR-T in 2L LBCL; granted RMAT, Fast Track, and Orphan Drug designations.","Chief Medical Officer Syed Rizvi to leave effective Dec 31, 2023; separation agreement with release required.","Search underway for new CMO; ANTLER dose expansion enrollment continues with 22 U.S. sites and 1 in Australia active."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-23-000134","json":"https://secwatch.observer/filing/0001619856-23-000134.json","markdown":"https://secwatch.observer/filing/0001619856-23-000134.md","text":"https://secwatch.observer/filing/0001619856-23-000134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000134/0001619856-23-000134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000134/crbu-20231211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:13:44.750648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07868ce653","claim":"Syed Rizvi departed as Chief Medical Officer at Caribou Biosciences, Inc..","evidence_excerpt":"Syed Rizvi, M.D., the Chief Medical Officer of Caribou Biosciences, Inc. (the “Company”), will be leaving the Company effective December 31, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000134/0001619856-23-000134-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"leaving"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}